Scheduled Conference Calls and Managements Changes - Analyst Notes on Spectranetics, Charles River, Chemed, WuXi PharmaTech and Ironwood Pharmaceuticals

NEW YORK, July 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding The Spectranetics Corporation (NASDAQ: SPNC), Charles River Laboratories (NYSE: CRL), Chemed Corporation (NYSE: CHE), WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE: WX) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4742-100free.

--
The Spectranetics Corporation Analyst Notes
On July 7, 2014, The Spectranetics Corporation (Spectranetics) announced that it will release its Q2 2014 financial results on Thursday, July 24, 2014, after the market closes, which will be followed by an investment-community conference call to discuss the results on the same day, beginning at 2:30 p.m. MT (4:30 p.m. ET). According to the Company, the conference call will be webcast on its website. A replay of the webcast will also be available on Spectranetics' website for 14 days following the completion of the call. The full analyst notes on Spectranetics are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/SPNC/report.pdf

--
Charles River Laboratories Analyst Notes
On July 7, 2014, Charles River Laboratories (Charles River) announced that it has scheduled the release of its Q2 2014 financial results on Wednesday, August 6, 2014, after the market closes, followed by a conference call to discuss the results on Thursday, August 7, 2014, at 9:00 a.m. ET. According to the Company, a live audio webcast of the call and a replay of the webcast will be available on its website. The full analyst notes on Charles River are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/CRL/report.pdf

--
Chemed Corporation Analyst Notes
On July 7, 2014, Chemed Corporation (Chemed) announced that it intends to release its Q2 2014 financial results on July 23, 2014, after the close of trading on the NYSE. On the following day, July 24, 2014, the Company has scheduled a conference call and webcast at 10:00 a.m. ET to discuss the results and provide an update on Chemed's business. The webcast can be accessed via the Company website, with a replay available beginning approximately two hours after the call's conclusion. The full analyst notes on Chemed are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/CHE/report.pdf

--
WuXi PharmaTech (Cayman) Inc. (ADR) Analyst Notes
On July 8, 2014, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that due to personal reasons, Ying Han resigned from the Company's Board of Directors, where she has served since 2008. WuXi stated that it has begun a search for a new board member to complete Ms. Han's term of office. Dr. Ge Li, Chairman and CEO, WuXi PharmaTech, said, "On behalf of the board, I want to thank Ying for her many years of excellent service as a WuXi board member. All of us at WuXi wish her the very best." The full analyst notes on WuXi PharmaTech are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/WX/report.pdf

--
Ironwood Pharmaceuticals, Inc. Analyst Notes
On July 7, 2014, Ironwood Pharmaceuticals, Inc. (Ironwood Pharmaceuticals) announced that it will host its Q2 2014 conference call on Monday, August 4, 2014, at 4:30 p.m. ET. According to the Company, a live webcast of the call will be available on its website. The archived webcast will also be available on Ironwood Pharmaceuticals' website, beginning at approximately an hour after the completion of the call, and will remain accessible for 14 days. The full analyst notes on Ironwood Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/IRWD/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED